Data suggest that SC pembrolizumab is non-inferior to IV pembrolizumab in patients with newly diagnosed, advanced NSCLC.

Subcutaneous pembrolizumab reduces time demands for both the patient and clinician, all while providing a consistent efficacy ...

Compared to the IV infusion of the blockbuster cancer drug Keytruda, subcutaneous Keytruda was able to reduce the time patients spent in the chemotherapy chair.